diagnostic and therapeutic potential in addition it will be a valuable tool for unravelling the role of integrin ?3 and CD26 in the progression and complex biology of pancreatic cancer
| Inventor | Institute |
|---|---|
| Helmout Modjtahedi | Kingston University |
| Cat. #: | 161583 |
|---|---|
| Tool sub type: | Primary antibody |
| Cancer types: | Pancreatic cancer |
| Research Fields: | Cancer |
| Application: | ELISA, IHC, IF, IP, WB, FACS |
| Target: | Integrin alpha3 |
| Reactivity: | Human |
| Clone: | KU44.22B |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Arias-Pinilla et al. 2020. Sci Rep. 10(1):537. PMID: 31953437 |
| Product description: | MAb KU44.22B inhibits the growth in vitro of Capan-2 cancer cells, increases migration of BxPC-3 and CFPAC-1 cancer cell lines and induces receptor downregulation and internalisation |
|---|---|
| Isotype: | IgG1 kappa |
| Molecular weight: | 110 kDa |
| Immunogen: | CFPAC-1 cell line |
| Target background: | Integrin alpha-3/beta-1 is a receptor for fibronectin, laminin, collagen, epiligrin, thrombospondin and CSPG4. Integrin alpha-3/beta-1 provides a docking site for FAP (seprase) at invadopodia plasma membranes in a collagen-dependent manner and hence may participate in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion. |
|---|
| Shipping conditions: | Dry ice |
|---|
| References: |
Arias-Pinilla et al. 2020. Sci Rep. 10(1):537. PMID: 31953437 |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.